ERBB2 and breast cancer: With the extensive use of monoclonal HER2-targeting antibodies, such as trastuzumab and pertuzumab, and antibody–drug conjugates, such as trastuzumab emtansine and trastuzumab deruxtecan, the systemic disease control and survival of patients with HER2-positive BC have dramatically improved [11,12,13].